ADMA Biologics Quarterly Cash Flow Statement
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics free cash flow
In the quarter ended Jun 30, 2026, ADMA Biologics generated $29.5 million of operating cash flow and spent $2.3 million on capital expenditures. That left free cash flow of $27.3 million, a free-cash-flow margin of 21.9% of revenue. Free cash flow was up 45.8% from the prior year's $18.7 million.
ADMA Biologics returned $25.1 million to shareholders through share repurchases, equal to 92% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 37.82M | 45.33M | 49.38M | 36.43M | 34.22M | 26.90M | 111.90M | 35.91M | 32.06M | 17.81M | -17.64M | 2.56M |
| Net Income growth (YoY) | +10.53% | +68.48% | -55.87% | +1.45% | +6.73% | +51.10% | — | +1299.96% | — | — | — | — |
| Depreciation & Amortization | 1.70M | 1.80M | 2.00M | 2.00M | 2.00M | 1.90M | 2.00M | 1.90M | 1.90M | 1.90M | 1.90M | 1.90M |
| Stock-Based Compensation | 6.13M | 6.33M | 5.39M | 5.05M | 4.96M | 4.62M | 5.43M | 3.18M | 2.86M | 2.14M | 1.75M | 1.70M |
| Change in Working Capital | -9.38M | 3.76M | -33.70M | -37.14M | -19.77M | -54.47M | 6.87M | -15.69M | 13.53M | -24.31M | -1.35M | 3.91M |
| Operating Cash Flow | 29.54M | 58.25M | 35.64M | 13.29M | 21.14M | -19.68M | 50.22M | 25.03M | 45.65M | -2.22M | 17.60M | 11.98M |
| Capital Expenditures | -2.26M | -2.54M | -1.08M | -14.37M | -2.42M | -4.70M | -2.76M | -1.06M | -2.07M | -2.35M | -1.20M | -757.00K |
| Investing Cash Flow | -2.26M | 2.40M | -276.00K | -14.37M | -2.53M | -4.72M | -2.75M | -1.10M | -2.37M | -2.36M | -1.41M | -757.00K |
| Share Repurchases | -25.05M | -130.19M | -8.90M | -23.04M | 0 | 0 | 0 | — | — | — | — | — |
| Financing Cash Flow | -29.42M | -10.13M | -9.12M | -27.82M | 48.00K | -7.13M | -31.03M | -25.47M | -362.00K | -1.45M | -38.99M | 416.00K |
| Net Change in Cash | -2.13M | 50.52M | 26.25M | -28.90M | 18.66M | -31.52M | 16.44M | -1.54M | 42.92M | -6.03M | -22.80M | 11.64M |
| Free Cash Flow | 27.28M | 55.71M | 34.55M | -1.07M | 18.72M | -24.38M | 47.46M | 23.97M | 43.58M | -4.57M | 16.40M | 11.23M |
This table shows 12 quarterly periods of ADMA Biologics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ADMA's reporting calendar. What is a cash flow statement?